115 results
Page 3 of 6
8-K
EX-99.1
qkjrby
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
8-K
EX-99.1
i5bx0lu pl
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
EX-99.1
c2e mhh3vo
10 Nov 22
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
4:29pm
8-K
EX-99.1
wlt14
8 Nov 22
Completion of Acquisition or Disposition of Assets
8:40am
8-K
6tuk6frg
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-99.2
wf59tj98 70bofxkp7i
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-99.1
oyw6co1embj8kl qx
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-4.3
jmkd k3ndw
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
424B4
sbv3rf15o 018koc
11 Oct 22
Prospectus supplement with pricing info
8:27am
FWP
5efv7 yjy
6 Oct 22
Free writing prospectus
4:05pm
8-K
EX-99.1
mvbfa b34se
22 Sep 22
Material Modifications to Rights of Security Holders
4:32pm